|
**Overview**: 21-Hydroxylase Deficiency Steroid Panel**Introduction**: The 21-Hydroxylase Deficiency Steroid Panel is a diagnostic tool designed to screen for 21-hydroxylase deficiency using serum samples. In India, 21-OH deficiency is the most common CAH form (~90 percent), presenting with salt-wasting crisis in neonates or virilization/precocious puberty in children. High morbidity from under-testing in rural/low-SES newborns with vomiting, dehydration, or ambiguous genitalia, limited endocrine labs, delayed glucocorticoid/mineralocorticoid replacement leading to shock or death. Per pediatric endocrinology practices aligned with ICMR and Indian Society for Pediatric and Adolescent Endocrinology guidelines, the test employs spectrophotometry for 17-OHP, cortisol, ACTH, androstenedione, and testosterone over 1-2 days with high accuracy, valuable for confirming diagnosis (elevated 17-OHP >1000 ng/dL diagnostic) and monitoring treatment. This diagnostic falls under endocrine screening and targets neonates/infants with crisis or virilization, addressing accurate detection to guide life-saving hormone replacement. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling early CAH confirmation and reducing neonatal mortality. Its serum-based approach ensures reliable steroid profiling.**Other Names**: 21-OH Def Pnl.**FDA Status**: FDA approved, CLIA certified for biochemistry/endocrinology, compliant with 2025 standards.**Historical Milestone**: 17-OHP screening standard in CAH; in India, key in NBS pilots.**Purpose**: The test assesses 5 parameters including 17-OHP to guide 21-OH deficiency screening, detect enzyme defect, inform replacement.**Test Parameters**: 1. 17-OHP, 2. Cortisol, 3. ACTH, 4. Androstenedione, 5. Testosterone.**Pretest Condition**: Fasting 10-12 hours recommended (if feasible); patients should have CAH suspicion.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve steroid integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients/parents should provide details on neonatal crisis, virilization.**Consent**: Written informed consent (parental) is required, detailing the test's purpose, potential risks of undetected CAH including shock, benefits of screening, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using spectrophotometry by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Markedly elevated 17-OHP + low cortisol indicates 21-OH deficiency, necessitating specialist input.**Specialist Consultation**: Pediatric endocrinologists should be consulted for management.**Additional Supporting Tests**: ACTH stimulation, genetic testing for confirmation.**Test Limitations**: Stress elevation in non-classic; comprehensive approach required.**References**: Indian Journal of Pediatrics 2024, Endocrine Studies India 2023. |
